XML 38 R59.htm IDEA: XBRL DOCUMENT
v3.19.3

License agreements - Innovent (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended
--- | --- | --- | ---
Jun. 30, 2019 | Jan. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018
License agreements |  |  |  |  |  |  |
Research and development |  |  |  | $ 281,336 | $ 292,527 | $ 841,244 | $ 893,719
Innovent |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  | $ 40,000 |  |  |  |  |
Research and development |  |  |  | 3,600 |  | 4,100 |
Reimbursable costs included in accounts receivable |  |  |  | $ 4,500 |  | $ 4,500 |
Innovent | Regulatory Milestones |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |
Milestone payment made under license agreement | $ 20,000 |  |  |  |  |  |
Innovent | Regulatory Milestones | Maximum |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  | $ 20,000 |  |  |  |
Innovent | Development and Regulatory Milestones | Maximum |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  | 129,000 |  |  |  |
Innovent | Commercialization Milestones | Maximum |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |
Upfront and immediate milestone payment to be received under license agreement |  |  | $ 202,500 |  |  |  |

X
- Definition Represents the amount of the milestone payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementMilestonePaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents reimbursable costs pertaining to license agreements. + References No definition available. + Details
Name: | incy_LicenseAgreementReimbursableCosts
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the upfront and immediate milestone payment received under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_InnoventBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |